التفاصيل البيبلوغرافية
| العنوان: |
Link between disease status at 24 months and mortality in follicular lymphoma. |
| المؤلفون: |
Rajamäki, Aino, Hujo, Mika, Sund, Reijo, Prusila, Roosa E. I., Kuusisto, Milla E. L., Kuitunen, Hanne, Jantunen, Esa, Mercadal, Santiago, Sorigue, Marc, Sancho, Juan‐Manuel, Kuittinen, Outi, Sunela, Kaisa |
| المصدر: |
British Journal of Haematology; Nov2022, Vol. 199 Issue 3, p458-462, 5p |
| مصطلحات موضوعية: |
FOLLICULAR lymphoma, BIOMARKERS, INFORMED consent (Medical law) |
| مستخلص: |
Keywords: follicular lymphoma; mortality; cause of death; event-free survival; progression of disease; POD24 EN follicular lymphoma mortality cause of death event-free survival progression of disease POD24 458 462 5 10/25/22 20221101 NES 221101 Although the life expectancy of patients with follicular lymphoma (FL) has improved considerably over the last 20 years,1-4 ~20% of patients still experience progression of disease within 24 months (POD24) of first-line therapy.5,6 This early progression is an established independent risk factor for poor survival.5-8 In addition, recent studies reported that complete remission (CR) at 24 months after diagnosis or 30 months after induction therapy predicts a similar life expectancy to that of the general population.9,10 This study aimed to evaluate the links between disease status at 24 months, mortality and causes of death in patients with FL. Within the 24 months of treatment, 174 patients (17.6%) experienced progression (POD24 patients), while 630 patients (63.6%) did not. However, Sarkozy et al.14 reported contrary findings suggesting that subsequent cumulative incidences of lymphoma-related and non-lymphoma-related mortality were similar amongst patients who were event-free at 24 months. In contrast, POD24 patients are at risk of early death due to progressive lymphoma, which justifies more aggressive therapies coupled with higher treatment-related mortality and morbidity and increased societal cost. [Extracted from the article] |
|
Copyright of British Journal of Haematology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |